DOP2014000127A - Benzotienilo-pirrolotriazinas disustituidas y sus usos - Google Patents
Benzotienilo-pirrolotriazinas disustituidas y sus usosInfo
- Publication number
- DOP2014000127A DOP2014000127A DO2014000127A DO2014000127A DOP2014000127A DO P2014000127 A DOP2014000127 A DO P2014000127A DO 2014000127 A DO2014000127 A DO 2014000127A DO 2014000127 A DO2014000127 A DO 2014000127A DO P2014000127 A DOP2014000127 A DO P2014000127A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compounds
- pirrolotriazinas
- disustituidas
- benzotienilo
- triazin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11193841 | 2011-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2014000127A true DOP2014000127A (es) | 2014-08-15 |
Family
ID=47326168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2014000127A DOP2014000127A (es) | 2011-12-15 | 2014-06-10 | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
Country Status (42)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10388493B2 (en) | 2011-09-16 | 2019-08-20 | Lam Research Corporation | Component of a substrate support assembly producing localized magnetic fields |
| UY34484A (es) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
| KR101974254B1 (ko) | 2013-07-18 | 2019-04-30 | 다이호야쿠힌고교 가부시키가이샤 | Fgfr 저해제의 간헐 투여용 항종양제 |
| HUE056048T2 (hu) * | 2013-10-21 | 2022-01-28 | Genosco | Helyettesített pirimidin vegyületek és SYK inhibitorként való alkalmazásuk |
| CN106999592A (zh) * | 2014-12-11 | 2017-08-01 | 拜耳医药股份有限公司 | 泛fgfr抑制剂的用途及鉴定患有适于用泛fgfr抑制剂治疗的癌症的患者的方法 |
| EA201791974A1 (ru) * | 2015-03-09 | 2018-05-31 | Байер Фарма Акциенгезельшафт | Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин |
| AU2016378723B2 (en) | 2015-12-22 | 2021-09-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| KR20180118719A (ko) | 2016-03-04 | 2018-10-31 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| WO2017172596A1 (en) | 2016-03-28 | 2017-10-05 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
| CN107513068A (zh) * | 2016-06-16 | 2017-12-26 | 中国科学院上海药物研究所 | 一种具有fgfr抑制活性的新型化合物及其制备和应用 |
| RU2753056C2 (ru) | 2016-12-16 | 2021-08-11 | Систик Файбросис Фаундейшн | Бициклические гетероарильные производные в качестве стимуляторов cftr |
| MA49458A (fr) | 2017-06-21 | 2020-04-29 | SHY Therapeutics LLC | Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques |
| WO2019034075A1 (zh) * | 2017-08-15 | 2019-02-21 | 南京明德新药研发股份有限公司 | Fgfr和egfr抑制剂 |
| JP7341122B2 (ja) * | 2017-08-15 | 2023-09-08 | 石薬集団中奇制薬技術（石家庄）有限公司 | Ｆｇｆｒ阻害剤及びその医薬品の用途 |
| CA3077308A1 (en) | 2017-09-27 | 2019-04-04 | Incyte Corporation | Salts of pyrrolotriazine derivatives useful as tam inhibitors |
| JOP20200090A1 (ar) | 2017-10-25 | 2020-05-03 | Bayer Pharma AG | عملية لتحضير بنزوثيوفين-2 يل بورونات |
| WO2019105734A1 (en) | 2017-11-28 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib |
| AU2019239404B2 (en) | 2018-03-19 | 2021-12-23 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
| WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
| PL3813800T3 (pl) | 2018-06-29 | 2025-08-18 | Incyte Corporation | Formulacje inhibitora axl/mer |
| EP3898609A1 (en) | 2018-12-19 | 2021-10-27 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| PH12021551812A1 (en) * | 2019-01-31 | 2022-03-21 | Bayer Ag | The monohydrate of rogaratinib hydrochloride and solid states thereof |
| CA3130247C (en) * | 2019-02-15 | 2024-02-13 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Fgfr inhibitor compound in solid form and preparation method therefor |
| WO2020170355A1 (ja) * | 2019-02-20 | 2020-08-27 | 大鵬薬品工業株式会社 | Ｆｇｆｒ１変異腫瘍の治療方法 |
| CN109928976A (zh) * | 2019-02-26 | 2019-06-25 | 泰州亿腾景昂药业有限公司 | 一种工业化生产eoc317的方法 |
| SG11202111327XA (en) * | 2019-05-13 | 2021-11-29 | Relay Therapeutics Inc | Fgfr inhibitors and methods of use thereof |
| WO2021089005A1 (zh) * | 2019-11-08 | 2021-05-14 | 石药集团中奇制药技术（石家庄）有限公司 | 一种fgfr抑制剂的用途 |
| CN111004234A (zh) * | 2019-11-28 | 2020-04-14 | 湖南农业大学 | 一种2-苯基咪唑并[1,2-α]吡啶类化合物的C3位卤化方法 |
| AU2021230385A1 (en) | 2020-03-06 | 2022-09-22 | Incyte Corporation | Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors |
| CN117402161A (zh) * | 2022-07-06 | 2024-01-16 | 上海科恩泰生物医药科技有限公司 | 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途 |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000071129A1 (en) * | 1999-05-21 | 2000-11-30 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| SK3792002A3 (en) | 1999-09-17 | 2003-09-11 | Abbott Gmbh & Co Kg | Kinase inhibitors as therapeutic agents |
| JPWO2004096806A1 (ja) * | 2003-04-30 | 2006-07-13 | 大日本住友製薬株式会社 | 縮合イミダゾール誘導体 |
| DE10327439A1 (de) * | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE602005014964D1 (de) | 2004-04-02 | 2009-07-30 | Osi Pharm Inc | Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren |
| UY28931A1 (es) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| TW200635927A (en) * | 2004-12-22 | 2006-10-16 | Bristol Myers Squibb Co | Synthetic process |
| WO2007056170A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| PT2385053E (pt) * | 2005-11-17 | 2013-12-17 | Osi Pharm Inc | Intermediários para a preparação de compostos bicíclicos condensados como inibidores mtor |
| US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| MX2008007103A (es) | 2005-12-02 | 2008-09-12 | Bayer Healthcare Llc | Derivados 4-amino-pirrolotriazina sustituidos, útiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis. |
| US8338594B2 (en) | 2005-12-02 | 2012-12-25 | Bayer Healthcare Llc | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
| PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
| TW201307354A (zh) * | 2005-12-29 | 2013-02-16 | Abbott Lab | 蛋白質激酶抑制劑 |
| US8124759B2 (en) | 2007-05-09 | 2012-02-28 | Abbott Laboratories | Inhibitors of protein kinases |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| EP2424368B1 (en) | 2009-04-29 | 2014-12-31 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
| UY34484A (es) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
-
2012
- 2012-12-03 UY UY0001034484A patent/UY34484A/es unknown
- 2012-12-10 ES ES12798738.6T patent/ES2591203T3/es active Active
- 2012-12-10 EP EP12798738.6A patent/EP2791140B1/en active Active
- 2012-12-10 PT PT127987386T patent/PT2791140T/pt unknown
- 2012-12-10 SG SG11201402325QA patent/SG11201402325QA/en unknown
- 2012-12-10 EA EA201400707A patent/EA029556B1/ru not_active IP Right Cessation
- 2012-12-10 MY MYPI2014701550A patent/MY178660A/en unknown
- 2012-12-10 HR HRP20161130TT patent/HRP20161130T1/hr unknown
- 2012-12-10 IN IN4310CHN2014 patent/IN2014CN04310A/en unknown
- 2012-12-10 DK DK12798738.6T patent/DK2791140T3/en active
- 2012-12-10 RS RS20160733A patent/RS55144B1/sr unknown
- 2012-12-10 PL PL12798738T patent/PL2791140T3/pl unknown
- 2012-12-10 LT LTEP12798738.6T patent/LT2791140T/lt unknown
- 2012-12-10 SI SI201230702A patent/SI2791140T1/sl unknown
- 2012-12-10 ME MEP-2016-181A patent/ME02517B/me unknown
- 2012-12-10 PE PE2014000926A patent/PE20141855A1/es active IP Right Grant
- 2012-12-10 WO PCT/EP2012/074977 patent/WO2013087578A1/en not_active Ceased
- 2012-12-10 HU HUE12798738A patent/HUE029582T2/en unknown
- 2012-12-10 CA CA2859133A patent/CA2859133C/en active Active
- 2012-12-10 MX MX2014006905A patent/MX367158B/es active IP Right Grant
- 2012-12-10 CN CN201280069882.6A patent/CN104245700B/zh not_active Expired - Fee Related
- 2012-12-10 BR BR112014014531-8A patent/BR112014014531B1/pt not_active IP Right Cessation
- 2012-12-10 US US14/365,424 patent/US20140336173A1/en not_active Abandoned
- 2012-12-10 KR KR1020147019406A patent/KR102057444B1/ko not_active Expired - Fee Related
- 2012-12-10 AU AU2012350750A patent/AU2012350750B2/en not_active Ceased
- 2012-12-10 JP JP2014546445A patent/JP6050829B2/ja not_active Expired - Fee Related
- 2012-12-10 CU CU2016000039A patent/CU24426B1/es unknown
- 2012-12-10 UA UAA201407930A patent/UA116768C2/uk unknown
- 2012-12-12 JO JOP/2012/0377A patent/JO3295B1/ar active
- 2012-12-12 AR ARP120104679A patent/AR089207A1/es unknown
- 2012-12-14 TW TW101147336A patent/TWI567076B/zh not_active IP Right Cessation
- 2012-12-14 US US13/715,553 patent/US9206184B2/en active Active
-
2014
- 2014-05-14 IL IL232611A patent/IL232611A/en active IP Right Grant
- 2014-06-09 CU CUP2014000065A patent/CU20140065A7/es unknown
- 2014-06-09 CO CO14123802A patent/CO7030961A2/es unknown
- 2014-06-10 DO DO2014000127A patent/DOP2014000127A/es unknown
- 2014-06-11 TN TNP2014000255A patent/TN2014000255A1/en unknown
- 2014-06-12 CL CL2014001547A patent/CL2014001547A1/es unknown
- 2014-06-12 EC ECIEPI20144722A patent/ECSP14004722A/es unknown
- 2014-06-13 GT GT201400113A patent/GT201400113A/es unknown
- 2014-06-13 PH PH12014501355A patent/PH12014501355A1/en unknown
- 2014-06-17 CR CR20140288A patent/CR20140288A/es unknown
- 2014-07-14 ZA ZA2014/05140A patent/ZA201405140B/en unknown
-
2016
- 2016-08-31 CY CY20161100853T patent/CY1118112T1/el unknown
-
2017
- 2017-07-17 AU AU2017206140A patent/AU2017206140A1/en not_active Abandoned
-
2018
- 2018-02-20 US US15/900,725 patent/US20190016724A1/en not_active Abandoned
-
2019
- 2019-06-18 AU AU2019204255A patent/AU2019204255A1/en not_active Abandoned
-
2021
- 2021-11-01 US US17/516,542 patent/US20220153745A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2014000127A (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| CL2013003227A1 (es) | “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct | |
| EA201492176A1 (ru) | Селективные ингибиторы pi3k дельта | |
| HUE061909T2 (hu) | Pirazolo[1,5-a]pirimidinek alkalmazása ATR kináz inhibítorként, rákos megbetegedések kezelésére | |
| GB201205669D0 (en) | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof | |
| EA201391416A1 (ru) | Новые соединения в качестве модуляторов протеинкиназ | |
| EA201790267A1 (ru) | Новые модуляторы киназ | |
| CL2012001303A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina sustituidas, inhibidores de la proteína quinasa raf; procedimiento de preparación; composición farmacéutica que los comprende; kit farmacéutico; y su uso para tratar melanoma, glioma, cáncer de pulmón, cáncer de hígado, alzheimer, parkinson, epilepsia, dolor neuropatico, aterosclerosis. | |
| GT201400057A (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
| UY32427A (es) | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma | |
| MX382354B (es) | Compuestos heterocíclicos y usos de los mismos. | |
| ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
| CL2011001378A1 (es) | Compuestos derivados de pirimidin oxi-indoles, inhibidores de vegf-r2; composicion farmaceutica que los comprende; uso en el tratamiento de una enfermedad o trastorno proliferativo tales como enfermedades tumorales y enfermedades de neovascularizacion ocular. | |
| EA201300987A1 (ru) | Фармацевтические композиции, включающие метформин и ингибитор dpp-4 или ингибитор sglt-2 | |
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| UY36586A (es) | Heterociclilmetiltienouracilos y uso de los mismos | |
| CL2012003637A1 (es) | Compuestos derivados de quinazolina o triazolopiridina sustituidos, inhibidores selectivos de tirosina quinasa; medicamento; composicion farmaceutica; y su uso para tratar, prevenir o mejorar edema retiniano/macular, degeneración macular relacionada con la edad y derrame vascular retiniano relacionado con isquemia, entre otras. | |
| EA201692255A1 (ru) | Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах | |
| MX2018009189A (es) | Compuestos de anillo de siete miembros de pirimidina. | |
| PE20190474A1 (es) | Tienouracilos n3-ciclicamente sustituidos y uso de los mismos | |
| MX374653B (es) | Derivados de cromeno sustituidos como inhibidores duales selectivos de proteínas cinasas pi3 delta y gamma. | |
| EA202092370A1 (ru) | Новые модуляторы киназ | |
| EA201990404A1 (ru) | Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах | |
| CR20150065A (es) | Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos |